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Transcriptomic profiling of feline 
teeth highlights the role of matrix 
metalloproteinase 9 (MMP9) 
in tooth resorption
S. Lee1*, S. J. Bush 2, S. Thorne3, N. Mawson1, C. Farquharson 1 & G. T. Bergkvist 1*
Tooth resorption (TR) in domestic cats is a common and painful disease characterised by the loss 
of mineralised tissues from the tooth. Due to its progressive nature and unclear aetiology the only 
treatment currently available is to extract affected teeth. To gain insight into TR pathogenesis, we 
characterised the transcriptomic changes involved in feline TR by sequencing RNA extracted from 
14 teeth (7 with and 7 without signs of resorption) collected from 11 cats. A paired comparison of 
teeth from the same cat with and without signs of resorption identified 1,732 differentially expressed 
genes, many of which were characteristic of osteoclast activity and differentiation, in particular matrix 
metalloproteinase 9 (MMP9). MMP9 expression was confirmed by qPCR and immunocytochemistry 
of odontoclasts located in TR lesions. A hydroxamate-based MMP9 inhibitor reduced both 
osteoclast formation and resorption activity while siRNA targeting MMP9 also inhibited osteoclast 
differentiation although had little effect on resorption activity. Overall, these results suggest that 
increased MMP9 expression is involved in the progress of TR pathogenesis and that MMP9 may be a 
potential therapeutic target in feline TR.
Tooth resorption (TR) of permanent teeth is the pathological loss of dental hard tissues and has been reported in 
many animals including humans, dogs, horses, domestic cats and wild  cats1–5. Affecting multiple teeth, resorp-
tion is common in aged domestic cats but is rarer in other  animals6–8. Destructive and progressive lesions usu-
ally initiate on the external surface of the coronal tooth root and extend into the cementum, enamel, dentine 
and in advanced stages, the  pulp7,9,10. TR largely classifies into three Types (Type 1–3) by the Nomenclature 
Committee of the American Veterinary Dental College (AVDC). Type 1 is characterised by appearance of focal 
or multifocal lesions of the tooth with normal periodontal ligament and inflammatory changes while Type 
2 presents resorption lesions with involvement of periodontal ligament and non-inflammatory replacement 
 resorption11. Type 3 exhibits both features of Type 1 and Type 2. TR is caused by tooth-resorbing odontoclasts, 
cells functionally similar to bone-resorbing  osteoclasts7. Both cell types are derived from circulating blood or 
bone marrow myeloid lineage progenitors which differentiate into mature multinucleated cells in their respective 
 microenvironments10,12–15. The main physiological role of odontoclasts is to resorb hard tissues around decidu-
ous teeth allowing tooth eruption to commence during tooth development and to resorb the deciduous teeth 
for permanent tooth  replacement16. In some cats these cells become dysregulated and attack the permanent 
teeth later in  life9,17. Due to recognition of this disease and investigations into the prevalence of TR between the 
1990s and 2000s, the aetiology of TR has been widely  studied9,18. The central axis of differentiation of osteoclasts 
and odontoclasts is the pathway comprising colony stimulating factor 1 (CSF-1) and the receptor activator of 
nuclear factor κ B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG), a decoy receptor, capturing 
 RANKL12,15. Since the microenvironments of physiological and pathologic TR are different, there has been a 
focus on identifying co-stimulating factors in pathological conditions. The accumulated evidence suggests that 
the initiation and progression of TR is complex and multifactorial and is also mediated by local rather than sys-
temic mechanisms. Many possible molecules and risk factors that directly or indirectly impact on the RANK/
RANKL/OPG axis pathway have been postulated, including pro-inflammatory  cytokines19,20,  diet21,22, thyroid 
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 hormones23, parathyroid  hormone24,25, parathyroid-related  peptides26, and vitamin D and its  metabolites17,27. 
However, the precise causes of TR in cats remain unknown.
Transcript identification and the quantification of gene expression have been distinct core activities in molecu-
lar biology ever since the discovery of RNA’s role as the key intermediate between the genome and the proteome. 
To our knowledge, no whole transcriptomic analysis of the feline tooth and dental microenvironment has been 
reported. We recently reported an optimised protocol for RNA extraction from cat teeth that produced RNA of 
acceptable quality for generation of cDNA libraries suitable for RNA-seq28. The aims of this study were firstly to 
perform RNA-seq analysis to compare the feline tooth transcriptome of normal and TR affected teeth. We then 
identified candidate genes related to feline odontoclastic regulation pathways and targeted them using RNA 
interference and inhibitors to further evaluate their role in odontoclast differentiation and odontoclast dentine 
resorption. The transcriptomic changes identified in TR teeth will help us further understand the pathogenesis of 
TR and help identify genes that can be considered potential therapeutic targets for the treatment of odontoclast 
dysregulation.
Material and methods
Tooth collection and phenotyping of TR. Teeth were collected from patients with full owner’s consent 
presented to the Hospital for Small Animals, The Royal (Dick) School of Veterinary Studies, The University 
of Edinburgh, UK. TR type and staging were confirmed by review of dental radiographs by veterinary dental 
specialists, S. Thorne and Dr Norman Johnston (MRCVS, RCVS, American & European Specialist in Veteri-
nary Dentistry, DentalVets, Haddington). Further research samples including teeth, maxilla, mandibles and long 
bones were collected at post mortem from cats euthanized for a wide range of medical or ethical reasons, not 
related to tooth resorption, and donated to the school for research. Ethical approval for the study was granted 
by the R(D)SVS veterinary ethical review committee (VERC reference 05.13). All methods were carried out in 
accordance with the relevant guidelines and regulations.
Tissue processing and RNA extraction. Samples including teeth, mandibles and maxilla were snap 
frozen in liquid nitrogen and stored at − 80  °C until RNA extraction. Information of samples are described 
in Table 1. Teeth were extracted from the alveolar sockets using dental equipment or using bone cutters while 
maintaining cold temperatures by working over dry ice. Tissue processing and RNA extraction protocols were 
optimised based on a guanidinium thiocyanate-phenol–chloroform extraction method and manufacturer’s 
instructions for the Qiagen RNeasy Mini Kit. This protocol has been previously  documented28.
cDNA library and RNA sequencing. Tested RNA samples were sent to our academic facility (Edin-
burgh Genomics, The University of Edinburgh, UK) for cDNA library production and RNA sequencing. Briefly, 
one microgram of RNA from each of the thirteen samples and 0.8 µg of RNA from one low quantity sample 
(N27C23TR+) were used to generate fourteen cDNA libraries using the Illumina TruSeq stranded mRNA sam-
ple preparation kit according to the manufacturer’s instructions (Illumina, San Diego, CA, USA). Paired-end 
sequencing was performed using the Hiseq 4000 system (Illumina). The low quality reads were filtered by Phred 
quality score (Q score 30) and 3′ adapter were trimmed with cutadapt (version 1.8.3). All the raw reads have 
Table 1.  Phenotyping of TR and selection of samples for RNA sequencing. RINe: the RNA integrity number 
equivalent, N/A: not applicable, F: female, N: RNA sample number, C: cat number, FN: female neutered, RNA 
yield shows total yield. PM; premolar, M; molar, C; canine.
Sample ID Extracted teeth
TR
status TR type TR stage
Description of TR 
status RINe
RNA yield
(mg) Age Sex
N14C12TR− Right/left 3rd and 4th PM − N/A N/A No TR lesion 4.5 10.3 4 F
N28C15TR− Right/left 3rd PM − N/A N/A No TR lesion 7.3 9.0 9 FN
N29C25TR− Right/left 3rd PM − N/A N/A No TR lesion 6.7 8.0 10 FN
N19C21TR− Left 4th PM − N/A N/A TR-toothfrom TR + cat 5.3 8.2 16 FN
N21C27TR− Right 3rd PM − N/A N/A Paired TR-tooth 4.1 8.4 7 FN
N23C30TR− Left 1st M − N/A N/A Paired TR-tooth 4.4 9.0 10 FN
N25C32TR− Left 4th PM − N/A N/A Paired TR-tooth 4.9 8.7 9 FN
N08C8TR+ Right/left 3rd PM  + 2 2 TR + tooth from TR + cat 5.2 5.8  > 5 F
N30C16TR+ Left 4th PM  + 2 2 TR+ tooth from TR + cat 4.7 9.1 5 FN
N27C23TR+ Right 4th PM  + 3 4 TR+ tooth from TR + cat 7.3 0.8 6 FN
N32C29TR+ Right 4th PM  + 3 4 TR+ tooth from TR + cat 7 9.7 7 FN
N22C27TR+ Right C  + 2 2 Paired TR + tooth 5.9 7.4 7 FN
N24C30TR+ Left 3rd PM  + 2 2 Paired TR + tooth 5.2 9.0 10 FN
N26C32TR+ Right 3rd PM  + 3 4 Paired TR + tooth 6.3 8.5 9 FN
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been submitted to the European Nucleotide Archive (ENA) under accession PRJEB24183 (ENA, https ://www.
ebi.ac.uk/ena). Assessment of quality control of RNA and cDNA library are stated  elsewhere28.
Mapping to the feline reference genome and generation of read counts. Alignments to the Felis 
catus genome (version 6.2) were performed using STAR (version 2.5)29. The read counts from each sample were 
generated using HTSeq (version 0.6.0.1)30 with mode ’union’. Duplicate reads were found using picard tools 
(version 1.141). Generation of MDS plots were generated using plotMDS function from edgeR package (version 
3.12.1) to visualise the level of similarity of individual cases of a dataset. From the 14 RNA-seq samples, two 
samples N27C23TR+ and N08C8TR+ were identified as outliers in MDS plots of RNA-seq data therefore they 
were excluded for final analysis (Fig. S1)28.
Differential expression analysis. ‘TR − ve cats’ are defined as teeth collected from a cat without any TR 
lesion and ‘TR + ve cats’ are teeth collected from a cat with at least one TR lesion. ‘TR tooth’ compares TR status 
of individual teeth, hence TR − ve teeth were collected from both TR free cats and TR diagnosed cats as long as 
the tooth was free of TR when assessed on dental radiographs. ‘Paired TR’ compares TR − ve teeth and TR + ve 
teeth from the same individuals, so a ‘within cat’ comparison.
From the remaining 12 libraries, three comparisons were performed: (1) TR − ve cats (n = 3) and TR + ve cats 
(n = 5), (2) TR − ve teeth (n = 7) and TR + ve teeth (n = 5), and (3) paired TR, TR − ve (n = 3) and TR + ve (n = 3). 
Differentially expressed (DE) genes were identified through comparisons between TR − ve and TR + ve groups 
using the R package edgeR (version 3.12.0)31. The trimmed mean of M-values normalization method was used. 
To explore sample dispersion between TR − ve and TR + ve groups, distance plot of biological coefficient of 
variation samples were generated and outliers were excluded for DE gene analysis. Significantly DE genes were 
identified using the threshold of false discovery rate (FDR)-adjusted p value < 0.05.
Enrichment analyses. We performed two enrichment analyses on the up- and downregulated DE genes: of 
KEGG (Kyoto Encyclopaedia of Genes and Genomes) metabolic  pathways32 and GO (Gene Ontology)  terms33. 
GO term enrichment was assessed using the R/Bioconductor package topGO v2.38.134. KEGG pathway enrich-
ment was performed using the R/Bioconductor package SPIA (Signalling Pathway Impact Analysis) v2.38.035.
Quantitative PCR. Real-time PCR was performed using the Takyon Low ROX SYBR 2X MasterMix kit 
(Eurogentec) in the Stratagene MX3000P qPCR system (Agilent Technologies). Each reaction contained 300 nM 
of gene of interest or reference gene primer, 2 × MasterMix, 4 μl of diluted cDNA and nuclease free water, pro-
ducing a final volume of 20 μl in a 96 well plate format. All samples were performed in duplicate and cycling 
threshold (Ct) values for each gene were generated. Calculation of relative gene expression analysis was based on 
delta-delta  method36,37. The primers used are described in Table S1.
Generation of feline osteoclasts in vitro. The protocol was modified from a published rodent osteoclast 
culture  protocol38. The long bones were dissected from cats at post mortem and cut off at the proximal and distal 
ends. Bone marrow was flushed out in α-MEM containing 10% FBS followed by red cell lysis in Lysis Buffer 
(150 mM  NH4Cl, 10 mM  NaHCO3, 0.1 mM EDTA) for 5 min, on ice. The bone marrow cells were resuspended 
in α-MEM containing 10% FBS, 2 mM L glutamine, 100 IU/ml benzyl penicillin, 100 mg/ml streptomycin, and 
CSF-1 (recombinant mouse CSF-1, 10 ng/ml, R&D Systems) and plated on a T75 flask for 24 h at 37 °C in 5% 
 CO2/95% air. On the following day, non-adherent cells were collected and plated on a dentine disc in each well of 
a 24 well plate (dentine discs were a generous gift from Professor Timothy R. Arnett, University College London, 
London, UK) or Corning Osteo Assay Surface multiple well plates (1 × 105 cells/cm2) with CSF-1 (10 ng/ml) at 
37 °C in 5%  CO2/95% air. On day 4, 90% of the medium was changed and, replaced with a new α MEM contain-
ing CSF-1 (10 ng/ml) and RANKL (recombinant mouse RANKL, 3 ng/ml, R&D Systems). The culture media 
was subsequently changed twice weekly for up to 10–14 days.
Characterisation of cultured osteoclast culture. Cultured osteoclasts on a cell culture plastic or den-
tine discs were washed twice with phosphate buffered saline (PBS) and fixed in 2.5% glutaraldehyde for 5 min. 
Tartrate resistant acid phosphatase (TRAP) activity was determined using Acid Phosphatase, Leukocyte (TRAP) 
Kit (Sigma-Aldrich) according to the manufacturer’s protocol with some modifications including reduced incu-
bation time (30 min) and without haematoxylin counter staining. TRAP positive cells were imaged via light 
microscopy (Leica DM LB2, Milton Keynes, UK). Cells were considered to be osteoclast-like when TRAP posi-
tive and with more than two nuclei when manually counted. Resorption pits in dentine discs were visualised 
and counted under light microscopy after removal of cells by sonication for 5 min in 0.25 M  NH4OH followed 
by 2 min toluidine blue staining.
Inhibition of MMP9 in osteoclastogenesis. The MMP9 inhibitor containing a hydroxamate (-CON-
HOH) group was purchased from Calbiochem (Merck Millipore, UK) and was reconstituted in DMSO (1 mg/
ml stock solution) and stored at − 20 °C. Primary feline osteoclasts derived from bone marrow were treated with 
a range of concentrations from 5 nM to 1 µM diluted in α-MEM until termination of osteoclast differentiation. 
Vehicle controls were treated with DMSO concentrations corresponding to the highest drug concentration used 
in the experiment. Untreated control cells were also included in each experiment.
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Targeting of siRNA of MMP9. The siRNA sequence against the feline MMP9 was designed using an 
online design tool, i-Score designer (i-score web service program). MMP9 feline siRNA targeting the MMP9 
mRNA sequence (CCA GGA GAC TTG CGA ACT A) was constructed using the Silencer siRNA Construction 
Kit (Ambion) according to the manufacturer’s protocol. Osteoclast precursors were incubated for two days in 
α-MEM containing 10% FBS, 2 mM L glutamine, 100 IU/ml benzyl penicillin, 100 mg/ml streptomycin, and 
CSF-1 (10 ng/ml) at 37 °C/5%  CO2. Cells were detached and resuspended for electroporation in 100 μl Mouse 
Macrophage Nucleofector solution and siRNA. The cell suspension–DNA mixture was transferred to Amaxa 
electrode cuvettes and electroporated in an Amaxa Nucleofector II (Lonza, UK) using program Y-001. Following 
electroporation, cells were immediately suspended in medium containing CSF1 (10 ng/ml) and RANKL (3 ng/
ml) and seeded into 96-well plates at 1 × 105 cells/well or onto dentine discs. Cells were incubated at 37 °C/5% 
 CO2 until osteoclast formation was observed in control wells. Media were changed every other day.
Immunohistochemistry of feline teeth. Feline tooth samples were collected and fixed by immersion 
in 10% neutral buffered formalin for 48 h before being processed. All fixed teeth were demineralised in EDTA 
pH 7.0 for 4–6 weeks at room temperature (RT). Demineralised samples were dehydrated and embedded in 
paraffin wax following standard procedures. Haematoxylin and Eosin (H & E) staining was performed using an 
autostainer (Leica Autostainer XL). For MMP9 immunostaining, slides were dewaxed and rehydrated. Antigen 
retrieval was performed in 0.1 M citrate buffer pH 6.0 for 90 min at 70 °C. Endogenous peroxidase was blocked 
using 1% hydrogen peroxidase in methanol for 30 min. A further blocking was carried out using a normal goat 
serum 1:5 in 5% FBS for 30 min. Primary MMP9 antibody (rabbit polyclonal; Abnova, PAB12714) was diluted 
1:200 in 5% of FBS in PBS and incubated at 4 °C overnight. Sections were washed and horseradish peroxidase 
labelled secondary antibodies (Envision Kit, Dako, UK) were added to the sections and incubated for 1 h at RT. 
Sections were washed 3 times with PBS for 5 min. Labelling was developed using ImmPACT DAB (Vector Labs, 
UK) at RT for 10 min producing a brown colour in positive sections and was counter-stained with haematoxylin.
Statistical analysis. All experiments were repeated at least twice on two separate occasions gaining similar 
results (except RNA-seq). In vitro experiments included triple to five technical replicates. Quantitative experi-
ments were analysed using Minitab 15 Statistical Software (Minitab Ltd., UK) and all graphs and diagrams were 
generated using Microsoft Office 2013 (Microsoft Corporation) or GraphPad prism v5 software. P values of less 
than 0.05 were deemed statistically significant. The two sample t-test or Mann Whitney U-tests were used to 
compare differences between two groups.
Results. RNA seq data of TR − ve and TR + ve teeth from the same cat (paired comparison) had the largest 
number of significantly DE genes. To explore the overall expression profiles between samples, multidimen-
sional scaling (MDS) plotting was used. MDS plot of TR − ve and TR + ve samples in both TR −/+ ve cats and TR 
−/+ ve teeth comparisons were closely plotted which implied their expression levels were similar (Fig. 1A,B). On 
the contrary, in the paired comparison, TR − ve samples were widely separated from TR + ve samples indicating 
possession of more DE genes than the other two comparisons (Fig. 1C). The smear plot allowed for visualisation 
of the relationship between overall expression level measured in counts per million (CPM) on the x axis and log2 
fold-change (FC) on the y axis where DE genes are displayed in red (Fig. 1D–F). The largest number of DE genes 
was observed in paired TR −/+ ve teeth, with 1,286 up-regulated genes and 466 down-regulated genes identified 
(Table 2). All expressed genes and significantly differentially expressed genes are listed in Table S2. Additionally, 
twenty seven differentially expressed genes were common for all three comparisons, including 25 up-regulated 
genes and 2 down-regulated genes (Table 3).
Pathway analysis revealed up-regulated genes that are involved in osteoclast differentiation 
and calcium signalling. For further characterisation of the transcriptomic changes involved in TR, enrich-
ment analyses were performed on the set of 1,732 genes DE between paired TR groups. KEGG downstream 
pathway analysis identified a total of 28 metabolic pathways within which these genes were involved (Table S3). 
Of these, the set of upregulated genes were enriched among the genes comprising 25 pathways, with the set of 
downregulated genes enriched only among 3 pathways. The most biologically relevant pathways were osteoclast 
differentiation (Fig. 2 and Table S3, KEGG pathway 04380; p = 0.03) and calcium signalling (Fig. 3 and Table S3, 
KEGG pathway 04020; p = 1.1 × 10–4) which promote the differentiation of osteoclast precursors and induce oste-
oclastic tooth resorption in teeth. Relative expression of each gene in each pathway was visualised with colour 
labels in Figs. 2 and 3. Identified pathways and their active status were revealed based on the expression of genes 
which constitute that pathway (Table S3). For instance, key genes in the osteoclast differentiation pathway were 
highly expressed in TR + ve teeth (Table S3, total number of genes in osteoclast differentiation pathway = 93, 
number of up-regulated differentially expressed genes = 15, down-regulated differentially expressed genes = 3). 
RANK is significantly up-regulated (Table 4, log2 fold change = 1.157, FDR = 0.0013) in TR + ve teeth. RANKL 
was not significantly up-regulated (Table S2, log2 fold change = 0.810, FDR = 0.253) but OPG was down-reg-
ulated (Table 4, log2 fold change = −1.326, FDR = 7.0 × 10–8), which led to an overall increase in the RANKL/
OPG ratio. Table 4 highlighted differentially expressed genes in osteoclast differentiation and calcium pathway 
with putative roles. Gene ontology enrichment analysis presented many gene sets involved in muscle physiol-
ogy including actin binding, myofibril, actin cytoskeleton, muscle contraction, heart contraction, muscle fibre 
development, skeletal muscle cell differentiation and muscle organ morphogenesis (Table S4).
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RT-qPCR validated the differential expression of the selected genes from RNA-seq 
result. Twelve candidate genes were functionally associated with osteoclast differentiation and activity 
(Tables  3 and 4) and were selected for validation by qPCR (Table  5). All genes considered significantly DE 
by RNA-seq (SPI1, MMP9, OPG, RANKL/OPG, ACP5, P2X2R, P2X4R, P2X6R, PCLB4, CA4 and CA6) were 
confirmed to be up-regulated in TR + ve teeth by qPCR. However, 3 genes considered DE by RNA-seq (CA4, 
P2X6R, and PCLB4) could not be confirmed by qPCR (Table 5). RANKL expression was unchanged but the gene 
Figure 1.  MDS plot and visualisation of gene expression data by smearplots. MDS plots of (A) TR −/+ cats 
comparison, (B) TR −/+ teeth comparison, and (C) paired TR −/+ comparison. Smear plots of (D) TR −/+ cats 
comparison, (E) TR −/+ teeth comparison, and (F) paired TR −/+ comparison. Lined circle: TR + ve samples, 
dotted circle: TR − ve (control teeth). Horizontal blue lines indicate fold-change of two. Red dot indicates each 
differentially expressed gene at False Discovery Rate or corrected p value (FDR) of 0.05 or smaller.
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expression ratio of RANKL/OPG was higher in TR + ve teeth (Fold change = 3.10, p = 0.036) compared to TR –ve 
teeth. CA6 was identified as the most highly upregulated gene in TR + ve teeth (Fold change = 5.51), followed by 
MMP9 (Fold change = 4.52), P2X2R (Fold change = 3.04), ACP5 (Fold change = 2.95), SPI1 (Fold change = 2.28) 
and P2X4R (Fold change = 2.28). CTSK was highly upregulated in TR + ve teeth by qPCR (p = 0.003) but not by 
RNA-seq (FDR = 0.059). Overall the gene expression profile of TR identified by RNA-seq was largely consistent 
with that of the qPCR analysis. Differential expression of MMP9 and P2X4R were re-confirmed by qPCR on a 
further six paired TR − ve and TR + ve teeth samples although this was not the case for SPI1, RANKL, OPG and 
RANKL/OPG (Fig. S2).
MMP9 is highly expressed in odontoclasts present in feline tooth resorption pits. MMP9 was 
successfully localised in feline dental tissues by immunohistochemistry (Fig. 4). Multinucleated odontoclast-like 
cells based on H&E staining (Fig. 4D,E) and MMP9 immunolabelled odontoclasts were identifiable in TR + ve 
sections (Fig. 4E,F) and there was no odontoclasts observed in TR − ve sections (Fig. 4A,B). Quantitative analy-
sis was not carried out due to the limited number of sections and number of active odontoclasts. Since aggre-
gated gingival epithelium also expressed some MMP9 (Fig. 4H), only multinucleated cells within an obvious 
resorption pit were considered to be odontoclasts. High expression of MMP9 was observed in actively resorbing 
odontoclasts in TR lesions (Fig. 4F,G). Fibroblasts of the periodontal ligament also expressed MMP9 in both TR 
− ve (Fig. 4B,C) and TR + ve teeth (Fig. 4F,G). It was also noted that the majority of TR + ve teeth had disrupted 
periodontal ligament fibres, narrowed or complete loss of periodontal ligament space and replacement with 
bone like tissues demonstrating a degree of ankylosis.
MMP9 expression was confirmed in cultured feline osteoclasts and increased upon osteoclast formation. 
MMP9 mRNA expression was significantly up-regulated in the early stages of osteoclast differentiation, with a 
7.8 ± 0.2 (p < 0.001) fold change on day 3 compared to day 0. MMP9 mRNA expression remained high until day 
6 where after it increased further 8.9 ± 0.2 (p = 0.0387) fold change on day 8 (Fig. 5).
Treatment with a semi-selective MMP9 inhibitor reduced osteoclast differentiation and resorp-
tion activity. In vitro osteoclast cultures were treated with a semi-selective MMP9 inhibitor (hydroxamate-
based MMP inhibitor). Inhibitory effects on osteoclast formation and resorption activity were observed in a 
Table 2.  Summary of differentially expressed genes from all comparisons. DE: differentially expressed, FDR: 
false discovery rate as adjusted p-value. Total number of expressed genes (Log2 counts per million > 1).
Comparison
Total number expressed 
genes
Number significantly 
DE genes
(FDR < 0.05)
Number upregulated 
genes
Number downregulated 
genes
TR- versus TR+ cats 13,243 315 279 36
TR- versus TR+ teeth 13,204 44 41 3
Paired TR- versuss TR + 13,121 1,732 1,286 446
Table 3.  Common genes from all three comparisons. LogFC; log2 fold change, LogCPM; log2 counts per 
million. Upregulated genes have log2 fold change > 0 and downregulated genes have log2 fold change < 0.
Gene Description LogFC LogCPM Gene Description LogFC LogCPM
Upregulated genes
CA6 Carbonic anhydrase VI 10.45 2.23 MUCIN7 Mucin 7, secreted 8.00 5.43
ARX Aristaless related homeobox 6.70 2.34 CHGB Chromogranin B 4.14 1.99
HOXA4 Homeobox A4 3.79 2.07 TECRL Trans-2,3-enoyl-CoA reductase-like 3.55 2.20
PPP1R27 Protein phosphatase 1 regulatory subunit 27 3.38 4.11 LBX1 Ladybird homeobox 1 3.12 2.10
METTL7B Methyltransferase like 7B 2.71 1.00 ATP1A3 ATPase, Na + /K + transporting, alpha 3 polypeptide 2.54 2.22
CA4 Carbonic anhydrase IV 2.53 2.73 ETNPPL Ethanolamine-phosphate phospho-lyase 2.52 3.34
SLC9A2 Solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2 2.41 3.48 CLDN10 Claudin 10 2.35 5.31
SMCO1 Single-pass membrane protein with coiled-coil domains 1 2.24 2.20 FAM166B Family with sequence similarity 166 member B 1.97 1.12
LDHD Lactate dehydrogenase D 1.96 4.37 TLX1 T-cell leukaemia homeobox 1 1.91 1.28
GRB14 Growth factor receptor bound protein 14 1.62 2.10 CHCHD10 Coiled-coil-helix-coiled-coil-helix domain contain-ing 10 1.58 5.84
ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 1.48 8.05 CES2 Carboxylesterase 2 1.21 3.69
IVD Isovaleryl-CoA dehydrogenase 1.08 5.86 KIF19 Kinesin family member 19 1.05 3.55
Downregulated gene
SOSTDC1 Sclerostin domain containing 1 − 1.05 4.06 KLK5 Kallikrein related peptidase 5 − 1.19 4.80
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dose dependent manner (Fig. 6). Osteoclast formation was not significantly reduced at low dose (5 nM, the half 
maximal inhibitory concentration = 5 nM) compared to vehicle control (p = 0.802), but the inhibitor significantly 
prevented osteoclast formation at higher doses, whereby 50 ± 6.3% (p < 0.0001) and 48.9 ± 5.8% (p < 0.0001) of 
the number of osteoclasts formed were observed compare to vehicle at 20 nM and 1000 nM treatments, respec-
tively (Fig. 6A). There was no difference in osteoclast numbers when increasing the concentration from 20 to 
1000 nM (p = 0.888). All three concentrations of MMP9 inhibitor resulted in reduction of resorption pits com-
pared to vehicle control (Fig. 6B). This inhibitory effect was dose dependent with 5, 20 and 1000 nM treatments 
producing 62.2 ± 7.4% (p = 0.002), 55.4 ± 8.8% (p = 0.0003) and 12.2 ± 2.5% (p = 0.001) of the number of resorp-
tion pits observed in the vehicle control, respectively.
MMP9 specific siRNAs causes a moderate reduction in mRNA levels and reduced the num-
ber of osteoclasts formed. Feline osteoclast precursors were transfected with feline MMP9 siRNA or 
a scrambled siRNA as control and seeded on dentine discs to investigate the role of MMP9 during osteoclast 
formation. Following electroporation of the osteoclast precursors with the MMP9 siRNA, a 44.00 ± 0.03% reduc-
tion (p = 0.0032) in MMP9 mRNA levels was observed in the transfected cells as assessed by qPCR at 48 h post 
transfection when compared to negative control transfected precursors (Fig. S3). Electroporation caused some 
cell death and therefore untransfected cells formed a higher number of osteoclasts and more resorption pits 
(Fig. 7B,D) but all groups of transfected cells were also able to differentiate into mature osteoclasts. Osteoclast 
formation was reduced (74.8 ± 7.2%; p < 0.0001) (Fig. 7A,B) in MMP9 siRNA transfected cells in comparison 
to scrambled siRNA control cells. However, no statistically significant differences in resorption activity was 
observed between scrambled siRNA and MMP9 siRNA treated wells (p < 0.2298) (Fig. 7).
Discussion
Current understanding of the aetiologies of feline TR is incomplete. Dysregulation of odontoclasts are respon-
sible for TR but the mechanisms underlying their dysregulation are largely unknown. The central aims of this 
study were to investigate the transcriptomic profile of TR affected cats, identify candidate genes related to feline 
odontoclast dysregulation and assess their potential as therapeutic targets.
First, we performed a RNA-seq to study the whole dental transcriptome of feline teeth and identify differen-
tially expressed genes correlated with progression of TR. No previous RNA-seq analysis of feline TR has been 
reported, but there are several dental transcriptomic studies using RNA-seq on rodent developing teeth and 
microarray studies on human teeth that suggested that different cells and tissues expressed unique transcriptomic 
Figure 2.  Osteoclast differentiation pathway (map04380) obtained from KEGG  database32 with official 
permission and guidance from Kanehisha Laboratories (permission ref 200,290). Expressed genes are coloured 
with red indicating relative up-regulation and with green indicating down-regulation in TR + ve teeth.
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profiles (e.g. between odontoblasts and pre-secretory ameloblasts or deciduous and permanent periodontal 
ligament and pulp)55–57.
In this study, we hypothesised that the transcriptome of TR affected teeth is locally different from TR free teeth 
and compared transcriptomic changes between TR − ve and TR + ve samples. There were only a few changes in 
gene expression that were common between all three comparisons of TR −/+ ve teeth, TR −/+ ve cat and paired 
TR − ve and TR + ve teeth and this may be due to large individual variations in the samples available. There were 
only limited genes identified in common between TR − ve and TR + ve teeth. The majority of remaining genes 
were uncharacterised or were not reported to be involved in tooth or osteoclast biology. Of these, carbonic anhy-
drase 4 (CA4) has been reported to be expressed in the plasma membrane of  osteoclasts58 and CA6 is known 
to be abundantly present in salivary glands and saliva and involved in maintenance of pH homeostasis in oral 
 cavity59,60. An oral microenvironment high in carbonic anhydrase may favour osteoclast  differentiation58. Some 
homeobox genes (e.g. ARX, HOXA4, LBX1, TLX1) has been reported in tooth  development61. One of the down-
regulated genes was SOSTDC1 which has been reported to be largely related to tooth development as an inhibi-
tor of Wnt signalling to control tooth number and  morphogenesis62,63. The role of these genes in TR + ve teeth 
are unclear but may suggest that permanent TR + ve teeth may undergo some form of remodelling  process61,64.
The paired TR comparison gave the most interesting results; a large number of transcripts from the TR + ve 
teeth differed from TR − ve teeth (n = 1732) which implies that these transcriptomic changes occur locally within 
the same dentition. The fact that there was transcriptomic similarity between teeth of the same phenotype and 
that the different phenotypes could clearly be separated reveals that the TR affected teeth undergo similar cellular 
and molecular changes. The transcriptome corresponding to the phenotype may suggest that transcriptomic 
changes are at the core of TR pathogenesis, and this knowledge has the potential to increase our understanding 
of the aetiology of TR.
Previous feline TR studies suggested that the local expression of inflammatory cytokines (e.g. IL1B, IL6, 
TNF and IFNG) and RANKL may be involved in feline TR, however expression of both pro-inflammatory 
and inhibitory-inflammatory cytokines increased in TR teeth than control by qPCR which makes it difficult to 
conclude and the local level of actual cytokines (protein) has however never been measured in  TR19,20. Therefore 
overall influence of inflammation cannot be conclusively determined. In human root resorption, P2X7R was 
considered a stimulator of osteoclast  differentiation65.
In this study, both RNA-seq data and qPCR result could not identify any significant changes in the expression 
of inflammatory cytokine genes between TR –ve and TR + ve teeth (e.g. IL1B, IL6, TNF, IFNG), P2X7R or VDR, 
Figure 3.  Calcium signalling pathway (map04020) obtained from KEGG  database32 with official permission 
and guidance from Kanehisha Laboratories (permission ref 200,290). Expressed genes are coloured with red 
indicating relative up-regulation and with green indicating down-regulation in TR + ve teeth.
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Table 4.  DE genes paired comparison. LogFC; log2 fold change, FDR: false discovery rate as adjusted p-value.
Gene status Gene name Description logFC FDR Putative function
Putative pathway: osteoclast differentiation
↑ SPI1(PU.1) Spi-1 proto-oncogene 1.028 0.0014 Induction of osteoclast  formation
39
↑ C-FMS(CSF1R) colony stimulating factor 1 receptor 1.026 1.37 × 10
–6 A trigger event leading to osteoclast differentiation via the c-Fms 
 receptor40
↑ TNFRSF11A (RANK) TNF receptor superfamily member 11a 1.157 0.0013
RANK/RANKL signalling is a central regulator of 
 osteoclastogenesis41↑ TNFSF11(RANKL) TNF superfamily member 11 0.810
#0.253
↑ OCSTAMP osteoclast stimulatory transmembrane protein 2.329 0.0030 Lack of cell–cell fusion of osteoclasts in OC-STAMP deficient  mice42
↑ ACP5 acid phosphatase 5, tartrate resistant 2.149 0.007 A cytochemical marker of  osteoclast43
↑ MMP9 matrix metallopeptidase 9 2.326 0.010 High expression in RANKL induced  osteoclasts44
↑ CALCR calcitonin receptor 1.896 0.036 Increase of calcitonin receptor during osteoclast  formation45
↑ CTSK cathepsin K 1.099 *0.059 Degradation of type I collagen by osteoclast-mediated bone  resorption46
↑ TREM2 triggering receptor expressed on myeloid cells 2 1.293 0.0027 Co-stimulatory receptor of RANK  signalling47
↑ TYROBP(DAP12) TYRO protein tyrosine kinase binding protein 0.764 0.0011
Osteopenia due to increase of osteoclasts in DAP12 overexpres-
sion  mice48
↑ CYBA(Nox1) cytochrome b-245 alpha chain 0.639 0.0080 MAPK activation via Nox1 in osteoclast  differentiation
49
↑ CYBB(Nox2) cytochrome b-245 beta chain 1.014 0.0146 Increase of Nox2 during RANKL induced  osteoclasts
49
↓ TNFRSF11B(OPG) TNF receptor superfamily member 11b − 1.326 7.0 × 10
–8 A negative regulator of  osteoclastogenesis41
↓ TGFB1 transforming growth factor beta 1 − 0.626 0.024
Inhibitory effect of TGF-β on osteoclast  differentiation50
↓ TGFB2 transforming growth factor beta 2 − 0.697 0.0055
Putative pathway: calcium signalling
↑ P2X2R purinergic receptor P2X2 1.962 4.3 × 10–4
Induction of  Ca2+ influx in osteoclast precursors and osteoclasts 
via extracellular ATP via various purinergic  receptors51–53↑ P2X4R purinergic receptor P2X4 0.786 0.0029
↑ P2X6R purinergic receptor P2X 6 2.700 1.26 × 10–5
↑ PLCB4 phospholipase C beta 4 1.106 3.36 × 10–5 Activated by  GPLC52,53
↓ P2X7R purinergic receptor P2X7 − 0.271 #0.639 Increased bone resorption by loss of function of P2 × 7r54
Table 5.  RNA-seq result validation by qPCR. Total n = 6 from TR –ve = 3, from TR + ve = 3, *; 0.05 < p < 0.1, **; 
p < 0.05 by student t-test.
Putative function Gene
RNA-seq qPCR
Expression in TR+ teeth Expression in TR+ 
Fold change normalised 
to TR- p value
Osteoclast differentiation
SPI1 ↑** ↑** 2.60 0.024
RANKL ↑ ↑ 1.35 0.279
OPG ↓** ↓** 0.44 0.037
RANKL/OPG – ↑** 3.10 0.036
Osteoclast genes
MMP9 ↑** ↑** 4.52 0.016
ACP5 ↑** ↑** 2.95 0.019
CTSK ↑* ↑** 2.81 0.003
Calcium signalling in 
osteoclast
P2X2R ↑** ↑** 3.04 0.025
P2X4R ↑** ↑** 2.28 0.039
P2X6R ↑** ↑* 2.81 0.079
PCLB4 ↑** ↑ 1.83 0.100
Common genes in TR + teeth 
(pH homeostasis)
CA4 ↑** ↑* 2.67 0.052
CA6 ↑** ↑** 5.51 0.040
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Fig. S4). It is possible that inflammation only appears at a particular stage of TR development so that the overall 
oral environment possesses a similar extent of inflammation within this study population. It has been reported 
that the prevalence of TR increased with age in random mixed breed cats although TR occurred regardless of 
age in pure breed  cats66,67. In our study population, the age range was broad (from 4 to 16 years), however the 
mean age (7.2 years) was similar to those in the previous studies (6.2 and 6.5 years)66,68. To avoid bias due to 
age, young cats were excluded (< 3 years) in our study and there was no statistically difference of the mean age 
between TR − ve (7.6 ± 3.2) and TR + ve cats (6.7 ± 1.9) (p = 0.68).
Another possible explanation for the lack of any changes in the expression levels of inflammatory cytokines 
could be due to a bias of TR type in this study. In this study, type 2 was the dominant type of TR (Table 1). It has 
been proposed that this type might be involved in non-inflammatory or idiopathic TR although other studies 
have not confirmed this  observation11,69,70. The finding that there is no change in RANKL mRNA levels was 
consistent with previous feline TR  studies19,20. It has been reported that RANKL is highly expressed in the peri-
odontal ligament of actively resorbing primary human  teeth71,72, whereas the level of RANKL mRNA is very low 
or not expressed in human adult  teeth73. In cats, RANKL mRNA levels in adult teeth and bones are  similar19. 
Since odontoclast activity is tightly controlled by the RANKL/OPG ratio, the level of OPG and RANKL mRNA 
expression should be considered together. In healthy feline permanent teeth, the level of OPG mRNA is signifi-
cantly higher than femoral or alveolar bone, providing evidence that the role of OPG may be a key factor, rather 
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Figure 4.  MMP9 is highly expressed in odontoclasts of feline tooth resorption lesions. H&E from TR − ve 
teeth (A) and TR + ve teeth (D,E). Immunohistochemical labelling for MMP9 protein with haematoxylin 
counterstaining TR − ve (B,C), TR + ve sections (F,G,H) and isotype control (I). No visible odontoclast is found 
in TR − ve teeth (B) and circle area of B is magnified in C. Resorbing odontoclasts (D, circle area) are magnified 
in E. MMP9 expression in TR − ve teeth are observed mainly in periodontal ligament or gingival tissues (B,C). 
TR + ve teeth contain active odontoclasts with resorption pits (F, dotted circle) with strong MMP9 expression, 
high magnification of this lesion (G). MMP9 expression was also found in multinucleated like cells but these 
cells did not reside in a resorption pit (H, arrow). AB alveolar bone, DE dentine, PDL periodontal ligament. 
Scale bars = 100 µm.
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than RANKL, in modulating odontoclast function in feline  TR19. This is supported by RNA-seq and qPCR data 
in the comparison of TR -/ + teeth from the same cat; the level of OPG mRNA level was low in the TR + ve teeth 
thus an increased RANKL/OPG ratio was observed in TR + ve teeth. However, the observation was not verified 
when repeated in a larger number of samples, hence the RANKL/OPG involvement in feline TR needs to be 
further investigated.
Based on the large number of DE genes, there were several interesting metabolic pathways identified. Specifi-
cally, DE genes were found which are reported to be involved in osteoclast differentiation (SPI1, C-FMS, RANK, 
RANKL, TREM2, DAP12, Nox1 and Nox2)39,41,48–51 or highly expressed in functional and mature osteoclast 
(OCSTAMP, ACP5, MMP9, CALCR and CTSK)42,43,45,46. SPI1, the gene encoding the haematopoietic transcrip-
tion factor PU.1, is essential for myeloid and B-lymphoid cell  development39. This was reported to be the earliest 
molecule which binds to sites in both the c-fms promoter or intronic regulatory element (FIRE enhancer) for 
commitment to osteoclast lineage in  mice40,74. The increased expression of SPI1 and C-FMS found in TR + ve teeth 
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comparison with the previous time point in culture, ###p < 0.001 in comparison with day 0 by two sample t test).
A BOsteoclast formation
Me
diu
m 
Ve
hic
le(
DM
SO
) 5 20
10
00
0
50
100
150
*** ***
###
MMP9 inhibitor nM
T
R
A
P
 p
o
si
ti
ve
o
st
eo
cl
as
ts
 (
%
 c
o
n
tr
o
l)
Resorption activity
Me
diu
m 
Ve
hic
le 
(D
MS
O)
 5 20
10
00
0
50
100
150
***
***
***
**
###
###
MMP9 inhibitor nM
R
es
o
rp
ti
o
n
 p
it
s 
(%
 c
o
n
tr
o
l)
MMP9 inhibitor (nM) MMP9 inhibitor (nM)
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may suggest that TR + ve teeth possess more odontoclast precursors in their environment which would be likely 
to form mature odontoclasts and induce tooth resorption. ACP5 and CTSK are recognised osteoclast markers 
in bone and  teeth43,46. Up-regulation of these genes also suggest increased odontoclast number and activity in 
TR teeth. MMP9 is a matrix metallopeptidase enzyme, gelatinase B and type IV collagenase. Its primary role is 
to degrade and remodel the extracellular matrix in many tissues including bone and  teeth75. Increased MMP9 
activity has been implicated in many diseases including osteoclastomas, Paget’s disease, bone fracture repair and 
dental pulp  inflammation76,77. It has also been reported that it is highly expressed in early stages of differentiating 
osteoclasts, mature osteoclasts as well as in odontoclasts in many species including human, mouse, rabbit and 
 cow78–80. Recently accumulated evidence suggests that MMP9 have an important role in the progression of caries, 
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Figure 7.  MMP9 siRNA transfected cells resulted in reduced osteoclast formation in comparison with 
scrambled control but there was no statistically significant difference in resorption activity. Representative 
images of TRAP positive osteoclasts on dentin discs from untransfected control, scrambled control and 
MMP9 siRNA transfected treatment (A). Representative images of toluidine blue stained resorption pits from 
untransfected control, scrambled control and MMP9 siRNA transfected treatment (C). Graphs represent 
percentage of number of osteoclasts (B) and resorption pits (D) with + SEM bars. (n = 3; ***p < 0.001 in 
comparison with scrambled control). Scale bars = 100 µm.
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specifically in the pulpal and periapical inflammation tissue destruction process. Significant elevation of MMP9 
expression was observed in apical periodontitis. MMP9 is synthesized and secreted by various stimulators such 
as physical agents or cell cytokines (IL1B and TNF-α)77. Interestingly, Zhang et al. (2020) suggested that MMP9 
may have anti-inflammatory  properties81. They showed that MMP9 knockout mice experimentally induced with 
apical periodontitis suffered a more severe inflammation than wild type mice. It was also reported that MMP9 
induced the reduction of IL1B, TNF-α, RANK, RANKL, TLR2, and TLR4 and increased OPG expression in LPS-
stimulated osteoblasts. These findings suggest that the role of MMP9 in bone destruction is complex and diverse 
and emphasises the role of MMP9 as an inflammatory regulator by  osteoblasts81. In our data, MMP9 expression 
was higher in TR + ve teeth but there was no difference in expression of inflammatory cytokines (IL1B, TNF-α) 
or RANK. Feline TR starts normally at the external root and neck area rather than within the pulp, and often 
results in ankylosis between tooth and alveolar bone rather than alveolar bone destruction. Feline TR is a unique 
phenomenon and might indicate slightly different pathogenesis from typical inflammation. Our study primarily 
focused on the role of the odontoclast, but it might be necessary to investigate further roles of other cell types 
comprising of the tooth (odontoblast, periodontal ligament cells). However, expression of MMP9 and its role 
in bone and tooth resorption has not previously been described in cats. One study reported high expression of 
MMP9 in feline  cancer82.
Another pathway identified, the calcium signalling pathway, controls multiple cellular functions in many cells 
via release of calcium ions from internal stores and its entry from the extracellular  fluid53. In particular, calcium 
signals in osteoclasts are responsible for diverse cellular functions including differentiation, bone resorption and 
gene  transcription52. Genes in calcium signalling might induce  Ca2+ influx thus contributing to osteoclast differ-
entiation (P2X2R, P2X4R, P2X6R, PLCB4)51–53. These genes are known to encode for nonselective cation channels 
permeable to  Ca2+ at the cellular level and thereby contribute to osteoclast differentiation. Originally, purinergic 
receptors were thought to play a role in ATP production which would in turn induce the formation and activa-
tion of  osteoclasts51,83. Purinergic receptors e.g. P2X7 or P2Y have been implicated as potent local inhibitors 
of matrix  mineralisation83. Expression of P2X2 receptor has been reported in both osteoblasts and osteoclasts 
but its precise role in bone is not  clear51. Up-regulation of P2X4 receptor has been attributed to inflammation 
via macrophage  invasion84. Although expression of the P2X6 receptor has not been reported in osteoclasts, its 
expression was reported to modulate the differentiation and migration of human mesenchymal stem  cells85. The 
roles of these genes (and their encoded proteins) in the dental microenvironment is largely unknown, so further 
studies are required to investigate their possible involvement in tooth resorption.
In addition to osteoclast biology, gene ontology enrichment analysis showed abundant genes involved in 
muscle physiology. Genes involved in structural myofibril components including ACTA1, ACTN2, ATP2A1, 
CSRP3, MYH11, MYOZ2, PDLIM3, SYNC, TCAP, TNNI1, TNNT3 and TPM2 were all up-regulated, however, 
the exact role of these genes in bone and tooth structure/function is unclear. These genes have also been identi-
fied to play a role in the development and differentiation of osteocytes, mechanosensing cells that coordinate the 
remodelling process mediated by osteoblasts and osteoclasts in developing bone and  tooth86. This manifestation 
is unexpected as adult teeth normally possess a limited ability to remodel. However, as TR + ve teeth showed a 
predominantly disrupted periodontal ligament, new bone formation (ankylosis) and external TR lesions in the 
root rather than internally, the noted changes in gene expression may reflect repair and some limited remodel-
ling in the roots of the TR + ve teeth, possibly resulting in the level of ankylosis noted in the histological sections. 
Of the above DE genes, we verified RNA-seq results with qPCR for the genes SPI1, OPG, MMP9, ACP5, CTSK, 
P2X2R, P2X4R, P2X6R and PCLB4 which all might be involved in osteoclast differentiation and activity, based 
on previous  reports43,46,51,74,75,87–89.
Finally, an in vitro feline osteoclast model was established to test the potential role of candidate genes. Since 
our data showed MMP9 was one of the most up-regulated genes in TR + ve teeth, it was chosen as a target for 
further investigation. Inhibition of MMP9 by a semi-selective synthetic inhibitor caused both a reduction of 
osteoclast formation and resorption activity. Synthetic MMP inhibitors have been developed for the treatment 
of several serious pathologies including periodontitis, although clinical trials gave disappointing results and 
only a few inhibitors (e.g. Periostat™) has been approved by the FDA for the treatment of periodontal  disease90. 
The synthetic inhibitor possesses a hydroxamic acid analogue which binds to the enzymatic sites of MMPs with 
high-affinity. However, members of MMPs family share a basic structure which comprises an auto-inhibitory 
pro-domain rendering them enzymatic latency, the catalytic domain, and the C-terminal hemopexin-like domain, 
for the recognition of MMP  substrates91. Although the inhibition of osteoclastic activity by the MMP9 inhibitor 
is concentration dependent, it is not clear if the effect of the MMP9 inhibitor is specific to MMP9 or not. There-
fore, MMP9 inhibitor experiments were confirmed using the gene specific siRNA approach. When inhibition 
of MMP9 mRNA was successfully performed by feline MMP9 siRNA, osteoclast formation was inhibited, but 
not resorption activity. The reduction of resorption activity by synthetic inhibitors but not by the more specific 
siRNA approach may be a result of off-target inhibition of other members of the MMP superfamily. These results 
suggest that the role for MMP9 in TR pathogenesis requires further investigation before any firm conclusions 
can be reached. Strong MMP9 expression both in osteoclasts and odontoclasts has been reported in bovine, 
rabbit and mice skeletal  tissue78,92, and was seen here in the histological tooth sections. Therefore MMP9 may 
be a potential therapeutic target in feline tooth resorption. The underlying mechanism of inhibition of osteoclast 
formation by MMP9 needs to be further investigated. Other candidate genes verified in this study could also 
be potential therapeutic targets in feline TR, and further studies, potentially looking at co-targeting of multiple 
targets should be performed.
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